PT-141 Half-Life — How Long Does Bremelanotide Stay in Your System?

PT-141 Half-Life: How Long Does Bremelanotide Stay in Your System?

Reviewed by the CoreSup Research Team · Based on FDA prescribing information for Vyleesi (bremelanotide), peer-reviewed pharmacokinetic studies, and clinical trial data · Updated March 2026

One of the most practical questions about any research compound is: how long does it last? For PT-141, the answer has two parts that many sources conflate. The plasma half-life — how quickly the compound clears your bloodstream — is approximately 2.7 hours. The duration of subjective effects — how long the changes in sexual desire and arousal persist — is typically 6–12 hours. These numbers mean different things and have different implications for research protocols.

This guide provides a complete pharmacokinetic breakdown of PT-141 (bremelanotide) based on data from the FDA-approved prescribing label and peer-reviewed clinical studies. It covers onset, peak concentration, elimination half-life, total clearance time, and factors that influence individual variation.

TL;DR: PT-141 has a plasma half-life of ~2.7 hours (FDA label). Onset begins at 45–60 minutes post-injection; peak plasma concentration (Tmax) at ~1 hour. Subjective effects on sexual desire last 6–12 hours despite faster plasma clearance. After 5 half-lives (~13.5 hours), ~97% of the compound has been eliminated. Standard drug tests do not screen for bremelanotide.

For a broader overview of PT-141, read our Complete PT-141 Guide for UAE Residents. For dosing specifics, see the PT-141 Dosage Guide.

PT-141 Pharmacokinetic Parameters — Official FDA Data

The PT-141 Timeline: From Injection to Clearance

Understanding PT-141's timeline requires distinguishing between pharmacokinetics (what the body does to the drug — absorption, distribution, metabolism, elimination) and pharmacodynamics (what the drug does to the body — receptor activation, subjective effects). These timelines do not run in parallel.

• 0 minutes: Subcutaneous injection administered to the abdomen, thigh, or upper arm. The lyophilised peptide (reconstituted with bacteriostatic water) or pre-mixed solution enters subcutaneous tissue.
• 15–30 minutes: Compound absorbed from subcutaneous depot into systemic circulation. Some users begin noticing early effects (warmth, mild flushing) during this phase.
• 45–60 minutes: Onset of primary effects. The FDA label instructs administration "at least 45 minutes before anticipated sexual activity." Plasma concentration is approaching Tmax. Nausea, if it occurs, typically begins in this window.
• 60 minutes (Tmax): Peak plasma concentration. Maximum receptor activation. Peak subjective effects on sexual desire, arousal, and (in men) erectile function. Nausea most pronounced in this window.
• 1–4 hours: Plasma concentration falling (T½ = 2.7 hrs). Nausea typically subsides by 2–3 hours. Subjective desire and arousal effects may remain elevated despite declining plasma levels — receptor-mediated pharmacodynamic effects outlast peak plasma concentration.
• 6–12 hours: Subjective effect window for most users. Sexual desire effects gradually diminish during this period.
• ~13.5 hours: Approximately 97% of the dose eliminated from plasma (5 × T½). The compound is effectively cleared for most practical purposes.

Why Subjective Effects Last Longer Than Plasma Half-Life Suggests

A common point of confusion: if PT-141's half-life is 2.7 hours, how can effects persist for 6–12 hours? This reflects a fundamental pharmacological principle: receptor occupancy and downstream signalling can persist after plasma drug levels fall.

When PT-141 binds to MC3R and MC4R receptors in the hypothalamus, it activates G-protein coupled receptor (GPCR) signalling cascades. These cascades generate second messengers (primarily cyclic AMP) that activate downstream transcription factors and neural circuits. This cellular signalling process has its own kinetics that are not directly coupled to plasma concentration. The receptor can remain in an activated or sensitised state even after plasma drug levels decline — a process called "pharmacodynamic persistence."

This is not unique to PT-141. Many CNS-active compounds exhibit a disconnect between plasma half-life and effect duration. The practical implication is that the 2.7-hour half-life does not mean effects wear off in 2.7 hours — it means plasma levels halve in that period. The full effect window is substantially longer.

Factors That Affect PT-141 Duration in Your System

Body Composition

PT-141 has a volume of distribution of approximately 40 litres — meaning it distributes into tissues beyond plasma. Individuals with higher body fat percentage may see a slightly extended effective window due to tissue redistribution, though this effect is modest given the peptide's relatively low lipophilicity.

Renal Function

The FDA label notes that renal clearance contributes to PT-141 elimination. In pharmacokinetic studies with participants with mild, moderate, and severe renal impairment, AUC (total drug exposure) increased by 1.4×, 2.0×, and 2.7× respectively compared to participants with normal renal function. For individuals with known renal impairment, this is clinically relevant — effective half-life is extended and side effect duration (particularly nausea) may be prolonged.

Age

Pharmacokinetic studies in older adults (≥65 years) showed approximately 1.4× higher AUC compared to younger adults, consistent with age-related reductions in renal clearance and metabolic capacity. Older researchers may find effects persist somewhat longer.

Dose

At higher doses, the absolute amount of compound in the system is greater, extending the time to reach the threshold below which receptor activation is insufficient to produce detectable effects. The FDA-approved dose is 1.75 mg. Research outside this approved context sometimes uses lower doses (0.5–1.0 mg) which would produce a shorter effective window.

Drug Interactions and Half-Life Implications

PT-141 is metabolised by proteolysis (peptide hydrolysis by circulating proteases and renal enzymes) rather than by cytochrome P450 (CYP450) hepatic enzymes. This is pharmacologically significant because the majority of known drug-drug interactions involve CYP450 pathways. PT-141 does not significantly inhibit or induce CYP450 enzymes, meaning it is unlikely to alter the metabolism of other CYP450-substrate drugs.

However, the FDA label includes two specific interaction warnings:

• Naltrexone: Co-administration with naltrexone (an opioid receptor antagonist used for alcohol use disorder and opioid dependence) decreased bremelanotide Cmax by 35% and AUC by 24%. If using PT-141 alongside naltrexone (including low-dose naltrexone protocols), the effective dose may be lower than expected.
• High-fat meals: While not a drug interaction, high-fat food intake before injection delays Tmax by approximately 1 hour and reduces Cmax by ~15%. This is a practical consideration for timing — administering on an empty or light-meal stomach produces faster, higher peak concentration.

Frequently Asked Questions

Need bacteriostatic water to reconstitute this peptide?

CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.

Shop Bacteriostatic Water →

Shop Featured Products

PT-141 Spray 10 mg

Buy Now

PT-141 10 mg

Buy Now